The European Bronchiectasis Registry (EMBARC) is one of the largest real-world bronchiectasis datasets globally, containing data from over 20,000 patients across more than 30 countries. This robust infrastructure supports international research and clinical trials, where AI-based imaging plays an important role in uncovering deeper disease phenotyping and mechanistic disease insights.
Through collaborative initiatives with study sponsors, Thirona has been providing quantitative CT analysis and was invited to participate in the imaging arm of the EMBARC-BRIDGE sub-study, supported by Chiesi Pharmaceuticals.
EMBARC-BRIDGE is a mechanistic initiative study in bronchiectasis, initiated to delineate underlying disease mechanisms and to identify molecular endotypes and phenotypes of bronchiectasis by merging imaging metrics with biological data.
Over 600 thoracic CT scans analyzed using advanced AI-based methods, with further analyses currently in progress
Integration of quantitative imaging biomarkers into the EMBARC registry, enhancing clinical data with objective structural CT metrics
Mechanistic study on EMBARC-BRIDGE sub-population to analyze 800-1000 scans pending
Thirona provides advanced quantitative CT analysis to deliver imaging-based insights and to help phenotype structural changes across both airways and lung parenchyma. Key measurements include:
